Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 20

1.

Genetic risk for malignant hyperthermia in non-anesthesia-induced myopathies.

Vladutiu GD, Isackson PJ, Kaufman K, Harley JB, Cobb B, Christopher-Stine L, Wortmann RL.

Mol Genet Metab. 2011 Sep-Oct;104(1-2):167-73. doi: 10.1016/j.ymgme.2011.07.001. Epub 2011 Jul 12.

2.

Ryanodine receptor mutations in malignant hyperthermia and central core disease.

McCarthy TV, Quane KA, Lynch PJ.

Hum Mutat. 2000;15(5):410-7. Review.

PMID:
10790202
3.

Core myopathies and malignant hyperthermia susceptibility: a review.

Brislin RP, Theroux MC.

Paediatr Anaesth. 2013 Sep;23(9):834-41. doi: 10.1111/pan.12175. Epub 2013 Apr 25. Review.

PMID:
23617272
4.

[Genetic of diseases by abnormal functioning of the skeletal muscle-calcium releasing complex].

Lunardi J, Monnier N.

Rev Neurol (Paris). 2004 May;160(5 Pt 2):S70-7. Review. French.

PMID:
15269663
5.

Core myopathies and risk of malignant hyperthermia.

Klingler W, Rueffert H, Lehmann-Horn F, Girard T, Hopkins PM.

Anesth Analg. 2009 Oct;109(4):1167-73. doi: 10.1213/ANE.0b013e3181b5ae2d. Review.

PMID:
19762745
6.

Dominant and recessive RYR1 mutations in adults with core lesions and mild muscle symptoms.

Duarte ST, Oliveira J, Santos R, Pereira P, Barroso C, Conceição I, Evangelista T.

Muscle Nerve. 2011 Jul;44(1):102-8. doi: 10.1002/mus.22009. Review.

PMID:
21674524
7.

Mutations in RYR1 in malignant hyperthermia and central core disease.

Robinson R, Carpenter D, Shaw MA, Halsall J, Hopkins P.

Hum Mutat. 2006 Oct;27(10):977-89. Review.

PMID:
16917943
8.
9.

Genetic predisposition to statin myopathy.

Vladutiu GD.

Curr Opin Rheumatol. 2008 Nov;20(6):648-55. doi: 10.1097/BOR.0b013e328314b7b4. Review.

PMID:
18946323
10.

Multiminicore myopathy, central core disease, malignant hyperthermia susceptibility, and RYR1 mutations: one disease with many faces?

Mathews KD, Moore SA.

Arch Neurol. 2004 Jan;61(1):27-9. Review. No abstract available.

PMID:
14732615
11.

Malignant hyperthermia.

Bandschapp O, Girard T.

Swiss Med Wkly. 2012 Jul 31;142:w13652. doi: 10.4414/smw.2012.13652. Review.

12.

Congenital muscle disorders with cores: the ryanodine receptor calcium channel paradigm.

Treves S, Jungbluth H, Muntoni F, Zorzato F.

Curr Opin Pharmacol. 2008 Jun;8(3):319-26. doi: 10.1016/j.coph.2008.01.005. Epub 2008 Mar 4. Review.

PMID:
18313359
13.

Malignant hyperthermia.

Rosenberg H, Davis M, James D, Pollock N, Stowell K.

Orphanet J Rare Dis. 2007 Apr 24;2:21. Review.

14.

DNA testing for malignant hyperthermia: the reality and the dream.

Stowell KM.

Anesth Analg. 2014 Feb;118(2):397-406. doi: 10.1213/ANE.0000000000000063. Review.

PMID:
24445638
15.

Malignant hyperthermia and associated disorders.

Allen GC.

Curr Opin Rheumatol. 1993 Nov;5(6):719-24. Review.

PMID:
8117533
16.

Genetics of malignant hyperthermia.

Brandom BW.

ScientificWorldJournal. 2006 Dec 28;6:1722-30. Review.

17.

Statin-associated myopathy: from genetic predisposition to clinical management.

Vrablik M, Zlatohlavek L, Stulc T, Adamkova V, Prusikova M, Schwarzova L, Hubacek JA, Ceska R.

Physiol Res. 2014;63 Suppl 3:S327-34. Review.

18.

Myalgias and Myopathies: Drug-Induced Myalgias and Myopathies.

Holder K.

FP Essent. 2016 Jan;440:23-7. Review.

PMID:
26734833
19.

Anesthetic considerations in myofibrillar myopathy.

Latham GJ, Lopez G.

Paediatr Anaesth. 2015 Mar;25(3):231-8. doi: 10.1111/pan.12516. Epub 2014 Sep 12. Review.

PMID:
25216331
20.

Genetic and immunologic susceptibility to statin-related myopathy.

Patel J, Superko HR, Martin SS, Blumenthal RS, Christopher-Stine L.

Atherosclerosis. 2015 May;240(1):260-71. doi: 10.1016/j.atherosclerosis.2015.03.025. Epub 2015 Mar 21. Review.

PMID:
25818852
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk